Drug Interaction Report

Ivosidenib and Bedaquiline: Interaction Details

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Ivosidenib

Tibsovo
+

Bedaquiline

Sirturo Sirturo®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Aug 8, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 130 documented Ivosidenib interactions, 121 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
probable
Severity
Major

What happens

Reduced bedaquiline exposure, reduced efficacy of bedaquiline and an increased risk of QT interval prolongation

Interaction Deep Dive

Avoid the concomitant use of bedaquiline (a CYP3A4 substrate) with strong CYP3A4 inducers that prolong QT interval, as it may decrease the systemic bedaquiline exposure and may reduce the therapeutic effect of bedaquiline. And, concomitant use may also result in additive prolongation effects on the QT interval. Monitor ECG before initiation of treatment, 2 weeks after initiation and during treatment. Obtain electrolytes at baseline and during treatment and correct electrolytes. Discontinue bedaquiline if there is evidence of serious ventricular arrhythmia or QTc interval greater than 500 ms1.

Why it happens (mechanism)

Induction of CYP3A4-mediated metabolism of bedaquiline; additive QT interval prolongation

Literature reports

2 reports — tap to read

a) Mean bedaquiline exposure (eg, AUC) was reduced by 52% (90% CI, -57% to -46% change) in a drug interaction study in which healthy subjects received a single dose of bedaquiline 300 mg concomitantly with the strong CYP3A4 inducer, rifAMPin, at a dose of 600 mg once daily for 21 days 1.

b) In a study, where bedaquiline was administered with the QTc prolonging drugs clofazimine and levoFLOXacin, 5% of patients in the 40-week bedaquiline treatment group experienced a QTc 500 ms or greater and 43% of patients experienced an increase in QTc 60 ms or greater over baseline. Of the clofazimine-and levoFLOXacin-treated patients in the 40-week control arm, 7% of patients experienced a QTc 500 ms or greater and 39% experienced an increase in QTc 60 ms or greater over baseline 1.

Common questions

Can I take Ivosidenib and Bedaquiline together?

Reduced bedaquiline exposure, reduced efficacy of bedaquiline and an increased risk of QT interval prolongation Always confirm with your pharmacist or prescriber before making any change.

How serious is the Ivosidenib and Bedaquiline interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Questions for your pharmacist

  • Does my dose of Ivosidenib or Bedaquiline need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: SIRTURO(R) oral tablets, bedaquiline oral tablets. Janssen Products, LP (per FDA), Horsham, PA, 2024. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.